Paradigm Diagnostics, now part of Exact Sciences, specializes in advanced cancer diagnostics through its flagship product, PCDx. This comprehensive next-generation sequencing test assesses 90 FDA-approved therapeutic associations in cancer, including clinical trials by testing mutations, copy number variations, tumor mutation burden, and protein expression. The company operates in the healthcare sector, specifically targeting oncologists and healthcare providers who require rapid and accurate diagnostic results to inform treatment decisions. Paradigm Diagnostics' business model revolves around providing timely and precise diagnostic services, generating revenue through the sale of its PCDx tests. The company promises a clinically relevant turnaround time of 3-5 business days from sample receipt to reporting, ensuring that healthcare providers receive actionable genomic insights swiftly. The process involves multiple steps, including sample receipt, DNA extraction, sequencing, and clinical interpretation, all designed to deliver accurate results even from the smallest specimens.

Keywords: cancer diagnostics, genomic insights, next-generation sequencing, FDA-approved, therapeutic associations, mutations, tumor burden, protein expression, rapid results, healthcare providers.